The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclatasvir therapy
Khairy, R., Esmail, M., hammad, S., sayed, M., ahmed, H., abdelrahim, S. (2021). The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclatasvir therapy. EKB Journal Management System, 2(2), 271-279. doi: 10.21608/mid.2021.54456.1099
Rasha Khairy; mona Esmail; safaa hammad; mohammed sayed; Hazem ahmed; soha abdelrahim. "The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclatasvir therapy". EKB Journal Management System, 2, 2, 2021, 271-279. doi: 10.21608/mid.2021.54456.1099
Khairy, R., Esmail, M., hammad, S., sayed, M., ahmed, H., abdelrahim, S. (2021). 'The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclatasvir therapy', EKB Journal Management System, 2(2), pp. 271-279. doi: 10.21608/mid.2021.54456.1099
Khairy, R., Esmail, M., hammad, S., sayed, M., ahmed, H., abdelrahim, S. The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclatasvir therapy. EKB Journal Management System, 2021; 2(2): 271-279. doi: 10.21608/mid.2021.54456.1099

The relation between interleukin 28B gene polymorphisms (rs8099917 and rs12980275) and the response of treatment of Hepatitis C Virus genotype 4 patients to Sofosbuvir and Daclatasvir therapy

Microbes and Infectious Diseases
Article 12, Volume 2, Issue 2, May 2021, Page 271-279  XML PDF (415.13 K)
Document Type: Original Article
DOI: 10.21608/mid.2021.54456.1099
View on SCiNiTO View on SCiNiTO
Authors
Rasha Khairy; mona Esmail; safaa hammad email ; mohammed sayed; Hazem ahmed; soha abdelrahim
Department of Microbiology and Immunology, Faculty of Medicine, Minia University, Egypt
Abstract
Background: The main line of treatment of hepatitis C in Egypt is direct acting antiviral drugs (DAAs) Objectives: the current study aimed to explore the effect of IL28B genetic polymorphism on HCV infection progression and response to the new treatment in difficulty to treat individuals with HCV genotype 4. Methods: we collected blood samples from 50 healthy individuals as a control and 150 HCV- patients receiving SOF/DCV with ribavirin combination. IL28B (rs8099917, rs12980275) genotyping was implemented using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method to detect its impact on HCV disease outcome. Results: Out of patients, 141(94%) were responders to treatment and 9 (6%) were non- responders. A total of 112 (74.7%) of patients belonged to mild to moderate stages of liver fibrosis and 38(25.3%) had moderate to severe stages. There was a significant increase in severity of fibrosis among non-responders (p value .0.05). significant differences between the different genotypes of IL28B rs12980275 are not detected among the study population. Conclusion: TT genotype of IL28B (rs8099917) may be a protective factor against infection and associated with probability of achieving SVR to combined SOF and DCV therapy in genotype 4 HCV patients. However, GG genotype is negatively associated with HCV infection outcome. IL28B rs12980275 variants had no association with HCV infection.
Keywords
DAAs (daclatasvir; sofosbuvir; ribavirin); HCV genotype 4; IL28B polymorphisms
Statistics
Article View: 539
PDF Download: 301